Search Within

Mariko Yabe

Formats
  1. Journal Article (25)
  2. Meeting Abstract (22)
  3. Research Letter (3)
  4. Correspondence (1)
Groups
  1. Department of Pathology and Laboratory Medicine (51)
  2. Hematologic Malignancies, Division of (38)
  3. Center for Hematologic Malignancies (37)
  4. Department of Medicine (37)
  5. GSK Faculty (25)
  6. Executive Committee, Center for Hematologic Malignancies (24)

More Groups

People
  1. Ahmet Dogan (26)
  2. Kseniya Petrova-Drus (19)
  3. Eli Diamond (18)
  4. Omar Abdel-Wahab (17)
  5. Benjamin Durham (16)
  6. Maria Arcila (12)

More People

Years
  1. 2025 (3)
  2. 2024 (4)
  3. 2023 (13)
  4. 2022 (1)
  5. 2021 (5)
  6. 2020 (13)

More Years

Publications
  1. Blood (8)
  2. Laboratory Investigation (5)
  3. Pediatric Blood and Cancer (4)
  4. American Journal of Surgical Pathology (2)
  5. Blood Advances (2)
  6. British Journal of Haematology (2)

More Publications

Publishers
  1. Nature Publishing Group (12)
  2. American Society of Hematology (10)
  3. Lippincott Williams & Wilkins (4)
  4. Wiley Periodicals, Inc (4)
  5. American Association for Cancer Research (3)
  6. American Society of Clinical Oncology (3)

More Publishers

Results (51)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Mutant PIK3CA is a targetable driver alteration in histiocytic neoplasms
    Journal Article

    Durham, B. H.; Hershkovitz-Rokah, O.; Abdel-Wahab, O.; Yabe, M.; Chung, Y. R.; Itchaki, G.; Ben-Sasson, M.; Asher-Guz, V. A.; Groshar, D.; Doe-Tetteh, S. A.; more...
    Blood Advances (2023)

    Fulltext@MSK | Save
  • Outcomes after interruption of targeted therapy in patients with histiocytic neoplasms
    Journal Article

    Reiner, A. S.; Durham, B. H.; Yabe, M.; Petrova-Drus, K.; Francis, J. H.; Rampal, R. K.; Lacouture, M. E.; Rotemberg, V.; Abdel-Wahab, O.; Panageas, K. S.; more...
    British Journal of Haematology (2023)

    Fulltext@MSK | Save
  • Enhanced clinical assessment of hematologic malignancies through routine paired tumor and normal sequencing
    Journal Article

    Ptashkin, R. N.; Ewalt, M. D.; Jayakumaran, G.; Kiecka, I.; Bowman, A. S.; Yao, J. J.; Casanova, J.; Lin, Y. T. D.; Petrova-Drus, K.; Mohanty, A. S.; more...
    Nature Communications (2023)

    Fulltext@MSK | Save
  • A Rare case of primary cutaneous gamma-delta T-cell lymphoma with aberrant B-cell marker expression
    Journal Article

    Trivedi, A.; Yabe, M.; Dogan, A.; Epstein-Peterson, Z. D.; Myskowski, P. L.; Arcila, M. E.; Linos, K.
    American Journal of Dermatopathology (2023)

    Fulltext@MSK | Save
  • CSF1R inhibition for histiocytic neoplasm with CBL mutations refractory to MEK1/2 inhibition
    Research Letter

    Diamond, E. L.; Francis, J. H.; Lacouture, M. E.; Rotemberg, V.; Yabe, M.; Petrova-Drus, K.; Ulaner, G. A.; Reddy, R.; Abdel-Wahab, O.; Durham, B. H.
    Leukemia (2023)

    Fulltext@MSK | Save
  • Overcoming barriers to tumor genomic profiling through direct-to-patient outreach
    Journal Article

    Doe-Tetteh, S. A.; Camp, S. Y.; Reales, D.; Crowdis, J.; Noronha, A. M.; Wolff, B.; Alano, T.; Galle, J.; Selcuklu, S. D.; Viale, A.; more...
    Clinical Cancer Research (2023)

    Fulltext@MSK | Save
  • Clinical characteristics and treatment outcomes in patients with histiocytic neoplasms harboring class 3 MAP2K1 mutations, including novel treatment with the ERK inhibitor ulixertinib
    Meeting Abstract

    Diamond, E. L.; Rosenblum, M.; Yabe, M.; Petrova-Drus, K.; Francis, J. H.; Rampal, R. K.; Lacouture, M. E.; Rotemberg, V. M.; Hatzoglou, V.; Young, R.; more...
    Pediatric Blood and Cancer (2023)

    Fulltext@MSK | Save
  • Efficacy of alpelisib in PI3K-driven langerhans cell histiocytosis
    Meeting Abstract

    Mazor, R. D.; Durham, B. H.; Abdel-Wahab, O. I.; Diamond, E. L.; Yabe, M.; Itchaki, G.; Ben-Sasson, M.; Hershkovitz-Rokah, O.; Shpilberg, O.
    Pediatric Blood and Cancer (2023)

    Fulltext@MSK | Save
  • A multinational series of 26 patients with mixed histiocytic neoplasms highlighting a diverse mutational landscape and superior efficacy of targeted therapies
    Meeting Abstract

    Diamond, E. L.; Durham, B. H.; Reiner, A. S.; Yabe, M.; Petrova-Drus, K.; Francis, J. H.; Rampal, R. K.; Ulaner, G. A.; Reddy, R.; Lacouture, M. E.; more...
    Pediatric Blood and Cancer (2023)

    Fulltext@MSK | Save
  • Activating STAT5B mutations can cause both primary hypereosinophilia and lymphocyte-variant hypereosinophilia
    Research Letter

    Umrau, K.; Naganuma, K.; Gao, Q.; Dogan, A.; Kizaki, M.; Roshal, M.; Liu, Y.; Yabe, M.
    Leukemia and Lymphoma (2023)

    Fulltext@MSK | Save